SUTRO
Live / Applied — Statement of use — non-final action mailed (as of 03 Feb 2026)
What this means for you
Not registered yet, but its 24 Mar 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97855620
- Mark type
- Design + words
- Filed
- 24 Mar 2023
- Published for opposition
- 21 May 2024
- Attorney of record
- Karen Won
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations for the immune system targeting immuno-oncology pathways; Pharmaceutical and biological preparations for use in oncology; Pharmaceuticals and biological preparations for prophylactic, diagnostic, and therapeutic use in treating, preventing, and managing cancer; Therapeutic agents for medical use, namely, proteins and derivatives, antibody-drug conjugates, immunostimulatory anti-drug conjugates, cytokines, bispecific antibodies, and engineered antibodies for destroying tumor cells and stimulating immune response; Vaccines; Bacterial lysate preparations and bacterial extract preparations, for use in the cell free production of therapeutic proteins and peptides for medica
- Class 040 — Treatment of materials: Custom manufacturing of pharmaceuticals and therapeutic agents for medical use; Custom manufacturing of bacterial lysate preparations and bacterial extract preparations
- Class 042 — Scientific and technological services: Research and development in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory anti-drug conjugates, cytokines, bispecific antibodies, engineered antibodies, oncology, and immunology; Providing medical scientific research information in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory anti-drug conjugates, cytokines, bispecific antibodies, engineered antibodies, oncology, and immunology; Drug discovery, custom design, and development services featuring therapeutic agents for the treatment and prevention of diseases
Owner
- Sutro Biopharma, Inc., South San Francisco, CA, US
- Sutro Biopharma, Inc., South San Francisco, CA, US
Prosecution history
- 03 Feb 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 03 Feb 2026 — NON-FINAL ACTION E-MAILED
- 03 Feb 2026 — SU - NON-FINAL ACTION - WRITTEN
- 13 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 05 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Jan 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 01 Jul 2025 — USE AMENDMENT FILED
- 02 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Jul 2025 — TEAS STATEMENT OF USE RECEIVED
- 02 Jul 2025 — SOU EXTENSION 2 GRANTED
- 01 Jul 2025 — SOU EXTENSION 2 FILED
- 01 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Jan 2025 — SOU EXTENSION 1 GRANTED
- 15 Jan 2025 — SOU EXTENSION 1 FILED